Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of Admilparant in Healthy Males
NCT04567667Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 15 days, Maximum observed plasma concentration of total radioactivity up to 15 days and 4 more. Started Oct 2020; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04567667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567667.